Synopsis
Bharat Biotech’s Covaxin is India’s first indigenous coronavirus vaccine. The DCGI’s approval of Covaxin, despite it not having phase-3 clinical trial efficacy and safety data, stunned several vaccine experts. Many expressed doubts about the company’s clinical trial processes. A moment of triumph became a defensive one for Bharat Biotech’s founder-CMD M Krishna Ella.
Related
In the midst of the lockdown in April, as the world was trying to get a handle on the nature of the novel coronavirus, a vehicle sped along the National Highway 65. Its occupants were aware of the urgency of their special mission that had started at the National Institute of Virology, Pune. However, despite the empty roads, the driver of the four-wheeler had to be careful. He could not afford an accident; the stakes were sky-high.
Here are 10 things to know about Bharat Biotech, its founder Krishna Ella
Ella said Bharat Biotech is investing Rs 100 crore on research and conducting clinical trials in FY2021. In addition, the company will invest up to Rs 200 crore in FY2021 and FY2022 for the development of a greenfield facility for a Covid-19 vaccine.
Krishna Ella, Chairman and Managing Director of Bharat Biotech.
With the restricted use approval of Bharat Biotech s Covid-19 vaccine Covaxin by India, both Bharat Biotech and its founder Chairman and Managing Director Krishna Ella, 73, have hogged the limelight.
Here are 10 things to know about Ella and his company